Bevacizumab is a humanized monoclonal antibody that is indicated as first-line treatment for mCRC in combination with chemotherapy [5], and its mechanism of action is based on its ability to bind to VEGF protein, thereby inhibiting tumor angiogenesis [24]. Here, VEGFA is linked to neoplasm.